US Inks $25 Million Deal to Fight Ebola With Moderna Technology

52
3
Favorite

US Inks $25 Million Deal to Fight Ebola With Moderna Technology

Bloomberg2023-01-11

Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（3）

blessed_1
·2023-01-11
Ok
Reply
Like
Report
kong1509
·2023-01-11
Ok
Reply
Like
Report
mm13
·2023-01-11
Wow.. another breakthrough
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1138355693?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-01-11 11:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138355693","market":"us","top_or_hot":-1,"title":"US Inks $25 Million Deal to Fight Ebola With Moderna Technology","media":"Bloomberg","content":"<div>\n<p>Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US Inks $25 Million Deal to Fight Ebola With Moderna Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS Inks $25 Million Deal to Fight Ebola With Moderna Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-11 11:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp","article_id":"1138355693","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138355693","pubTimestamp":1673407870,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection fr","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"美国签署2500万美元协议，利用现代技术抗击埃博拉病毒","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense contract worth up to $25 million to develop vaccines using Moderna Inc.’s messenger RNA technology.Scientists at University of Texas Medical Branch at Galveston, in partnership with Moderna, were awarded $13.5 million over three years to design, manufacture and test mRNA vaccines for Ebola and other lethal pathogens. The project covers the shots’ development through Phase 1 clinical trials and UTMB could receive an additional $11.1 million to study alternative ways of administering the vaccines.The contract is part of a broader push by the US to protect military personnel using technology that enabled the quick development of Covid-19 vaccines early in the pandemic.“The high mortality rate and the potential use of these viruses as an agent of bioterrorism remains a risk that necessitates an urgent development of a vaccine,” the UTMB said in a statement Tuesday.Bloomberg first reported details of the US government contract in October.Funding for the UTMB-Moderna project will come from offices within the Department of Defense and Department of Health and Human Services, both of which have strategic investments in technology that could enhance US preparedness against biological threats. The work will be carried out at the UTMB’s Sealy Institute of Vaccine Sciences.The scientists will focus on a family of pathogens that includes Ebola, Sudan and Marburg, as well as Lassa viruses, all of which have long topped the list of vaccine priorities for the US government. The viruses cause sporadic outbreaks throughout the world — most recently in Uganda — and typically have a high death toll.There are currently no vaccines approved by the US Food and Drug Administration for Sudan virus, Marburg or Lassa fever. There is only one vaccine in the US that is licensed to protect against Ebola.Representatives from the Defense Department and Moderna didn’t immediately respond to request for comment.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9951118398,"gmtCreate":1673420016514,"gmtModify":1676538833838,"author":{"id":"4112410321254552","authorId":"4112410321254552","name":"blessed_1","avatar":"https://community-static.tradeup.com/news/71622697830d9517eb67a61917d8a95f","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"idStr":"4112410321254552","authorIdStr":"4112410321254552"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9951118398","repostId":1138355693,"repostType":4,"repost":{"id":"1138355693","pubTimestamp":1673407870,"share":"https://ttm.financial/m/news/1138355693?lang=&edition=fundamental","pubTime":"2023-01-11 11:31","market":"us","language":"en","title":"US Inks $25 Million Deal to Fight Ebola With Moderna Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1138355693","media":"Bloomberg","summary":"Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection fr","content":"<html><head></head><body><ul><li>Texas scientists to study vaccines for several deadly viruses</li><li>US is seeking out greater protection from biological threats</li></ul><p>University of Texas researchers have clinched a US Department of Defense contract worth up to $25 million to develop vaccines using Moderna Inc.’s messenger RNA technology.</p><p>Scientists at University of Texas Medical Branch at Galveston, in partnership with Moderna, were awarded $13.5 million over three years to design, manufacture and test mRNA vaccines for Ebola and other lethal pathogens. The project covers the shots’ development through Phase 1 clinical trials and UTMB could receive an additional $11.1 million to study alternative ways of administering the vaccines.</p><p>The contract is part of a broader push by the US to protect military personnel using technology that enabled the quick development of Covid-19 vaccines early in the pandemic.</p><p>“The high mortality rate and the potential use of these viruses as an agent of bioterrorism remains a risk that necessitates an urgent development of a vaccine,” the UTMB said in a statement Tuesday.</p><p>Bloomberg first reported details of the US government contract in October.</p><p>Funding for the UTMB-Moderna project will come from offices within the Department of Defense and Department of Health and Human Services, both of which have strategic investments in technology that could enhance US preparedness against biological threats. The work will be carried out at the UTMB’s Sealy Institute of Vaccine Sciences.</p><p>The scientists will focus on a family of pathogens that includes Ebola, Sudan and Marburg, as well as Lassa viruses, all of which have long topped the list of vaccine priorities for the US government. The viruses cause sporadic outbreaks throughout the world — most recently in Uganda — and typically have a high death toll.</p><p>There are currently no vaccines approved by the US Food and Drug Administration for Sudan virus, Marburg or Lassa fever. There is only one vaccine in the US that is licensed to protect against Ebola.</p><p>Representatives from the Defense Department and Moderna didn’t immediately respond to request for comment.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US Inks $25 Million Deal to Fight Ebola With Moderna Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS Inks $25 Million Deal to Fight Ebola With Moderna Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-11 11:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138355693","content_text":"Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense contract worth up to $25 million to develop vaccines using Moderna Inc.’s messenger RNA technology.Scientists at University of Texas Medical Branch at Galveston, in partnership with Moderna, were awarded $13.5 million over three years to design, manufacture and test mRNA vaccines for Ebola and other lethal pathogens. The project covers the shots’ development through Phase 1 clinical trials and UTMB could receive an additional $11.1 million to study alternative ways of administering the vaccines.The contract is part of a broader push by the US to protect military personnel using technology that enabled the quick development of Covid-19 vaccines early in the pandemic.“The high mortality rate and the potential use of these viruses as an agent of bioterrorism remains a risk that necessitates an urgent development of a vaccine,” the UTMB said in a statement Tuesday.Bloomberg first reported details of the US government contract in October.Funding for the UTMB-Moderna project will come from offices within the Department of Defense and Department of Health and Human Services, both of which have strategic investments in technology that could enhance US preparedness against biological threats. The work will be carried out at the UTMB’s Sealy Institute of Vaccine Sciences.The scientists will focus on a family of pathogens that includes Ebola, Sudan and Marburg, as well as Lassa viruses, all of which have long topped the list of vaccine priorities for the US government. The viruses cause sporadic outbreaks throughout the world — most recently in Uganda — and typically have a high death toll.There are currently no vaccines approved by the US Food and Drug Administration for Sudan virus, Marburg or Lassa fever. There is only one vaccine in the US that is licensed to protect against Ebola.Representatives from the Defense Department and Moderna didn’t immediately respond to request for comment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9951131814,"gmtCreate":1673416474339,"gmtModify":1676538833423,"author":{"id":"4112855949003692","authorId":"4112855949003692","name":"kong1509","avatar":"https://community-static.tradeup.com/news/5c7779ca51cd488037d326183dfd5994","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4112855949003692","authorIdStr":"4112855949003692"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9951131814","repostId":1138355693,"repostType":4,"repost":{"id":"1138355693","pubTimestamp":1673407870,"share":"https://ttm.financial/m/news/1138355693?lang=&edition=fundamental","pubTime":"2023-01-11 11:31","market":"us","language":"en","title":"US Inks $25 Million Deal to Fight Ebola With Moderna Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1138355693","media":"Bloomberg","summary":"Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection fr","content":"<html><head></head><body><ul><li>Texas scientists to study vaccines for several deadly viruses</li><li>US is seeking out greater protection from biological threats</li></ul><p>University of Texas researchers have clinched a US Department of Defense contract worth up to $25 million to develop vaccines using Moderna Inc.’s messenger RNA technology.</p><p>Scientists at University of Texas Medical Branch at Galveston, in partnership with Moderna, were awarded $13.5 million over three years to design, manufacture and test mRNA vaccines for Ebola and other lethal pathogens. The project covers the shots’ development through Phase 1 clinical trials and UTMB could receive an additional $11.1 million to study alternative ways of administering the vaccines.</p><p>The contract is part of a broader push by the US to protect military personnel using technology that enabled the quick development of Covid-19 vaccines early in the pandemic.</p><p>“The high mortality rate and the potential use of these viruses as an agent of bioterrorism remains a risk that necessitates an urgent development of a vaccine,” the UTMB said in a statement Tuesday.</p><p>Bloomberg first reported details of the US government contract in October.</p><p>Funding for the UTMB-Moderna project will come from offices within the Department of Defense and Department of Health and Human Services, both of which have strategic investments in technology that could enhance US preparedness against biological threats. The work will be carried out at the UTMB’s Sealy Institute of Vaccine Sciences.</p><p>The scientists will focus on a family of pathogens that includes Ebola, Sudan and Marburg, as well as Lassa viruses, all of which have long topped the list of vaccine priorities for the US government. The viruses cause sporadic outbreaks throughout the world — most recently in Uganda — and typically have a high death toll.</p><p>There are currently no vaccines approved by the US Food and Drug Administration for Sudan virus, Marburg or Lassa fever. There is only one vaccine in the US that is licensed to protect against Ebola.</p><p>Representatives from the Defense Department and Moderna didn’t immediately respond to request for comment.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US Inks $25 Million Deal to Fight Ebola With Moderna Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS Inks $25 Million Deal to Fight Ebola With Moderna Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-11 11:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138355693","content_text":"Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense contract worth up to $25 million to develop vaccines using Moderna Inc.’s messenger RNA technology.Scientists at University of Texas Medical Branch at Galveston, in partnership with Moderna, were awarded $13.5 million over three years to design, manufacture and test mRNA vaccines for Ebola and other lethal pathogens. The project covers the shots’ development through Phase 1 clinical trials and UTMB could receive an additional $11.1 million to study alternative ways of administering the vaccines.The contract is part of a broader push by the US to protect military personnel using technology that enabled the quick development of Covid-19 vaccines early in the pandemic.“The high mortality rate and the potential use of these viruses as an agent of bioterrorism remains a risk that necessitates an urgent development of a vaccine,” the UTMB said in a statement Tuesday.Bloomberg first reported details of the US government contract in October.Funding for the UTMB-Moderna project will come from offices within the Department of Defense and Department of Health and Human Services, both of which have strategic investments in technology that could enhance US preparedness against biological threats. The work will be carried out at the UTMB’s Sealy Institute of Vaccine Sciences.The scientists will focus on a family of pathogens that includes Ebola, Sudan and Marburg, as well as Lassa viruses, all of which have long topped the list of vaccine priorities for the US government. The viruses cause sporadic outbreaks throughout the world — most recently in Uganda — and typically have a high death toll.There are currently no vaccines approved by the US Food and Drug Administration for Sudan virus, Marburg or Lassa fever. There is only one vaccine in the US that is licensed to protect against Ebola.Representatives from the Defense Department and Moderna didn’t immediately respond to request for comment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9951378529,"gmtCreate":1673408405061,"gmtModify":1676538832152,"author":{"id":"4133006287772432","authorId":"4133006287772432","name":"mm13","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4133006287772432","authorIdStr":"4133006287772432"},"htmlText":"Wow.. another breakthrough&nbsp;","listText":"Wow.. another breakthrough&nbsp;","text":"Wow.. another breakthrough","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9951378529","repostId":1138355693,"repostType":2,"repost":{"id":"1138355693","pubTimestamp":1673407870,"share":"https://ttm.financial/m/news/1138355693?lang=&edition=fundamental","pubTime":"2023-01-11 11:31","market":"us","language":"en","title":"US Inks $25 Million Deal to Fight Ebola With Moderna Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1138355693","media":"Bloomberg","summary":"Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection fr","content":"<html><head></head><body><ul><li>Texas scientists to study vaccines for several deadly viruses</li><li>US is seeking out greater protection from biological threats</li></ul><p>University of Texas researchers have clinched a US Department of Defense contract worth up to $25 million to develop vaccines using Moderna Inc.’s messenger RNA technology.</p><p>Scientists at University of Texas Medical Branch at Galveston, in partnership with Moderna, were awarded $13.5 million over three years to design, manufacture and test mRNA vaccines for Ebola and other lethal pathogens. The project covers the shots’ development through Phase 1 clinical trials and UTMB could receive an additional $11.1 million to study alternative ways of administering the vaccines.</p><p>The contract is part of a broader push by the US to protect military personnel using technology that enabled the quick development of Covid-19 vaccines early in the pandemic.</p><p>“The high mortality rate and the potential use of these viruses as an agent of bioterrorism remains a risk that necessitates an urgent development of a vaccine,” the UTMB said in a statement Tuesday.</p><p>Bloomberg first reported details of the US government contract in October.</p><p>Funding for the UTMB-Moderna project will come from offices within the Department of Defense and Department of Health and Human Services, both of which have strategic investments in technology that could enhance US preparedness against biological threats. The work will be carried out at the UTMB’s Sealy Institute of Vaccine Sciences.</p><p>The scientists will focus on a family of pathogens that includes Ebola, Sudan and Marburg, as well as Lassa viruses, all of which have long topped the list of vaccine priorities for the US government. The viruses cause sporadic outbreaks throughout the world — most recently in Uganda — and typically have a high death toll.</p><p>There are currently no vaccines approved by the US Food and Drug Administration for Sudan virus, Marburg or Lassa fever. There is only one vaccine in the US that is licensed to protect against Ebola.</p><p>Representatives from the Defense Department and Moderna didn’t immediately respond to request for comment.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US Inks $25 Million Deal to Fight Ebola With Moderna Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS Inks $25 Million Deal to Fight Ebola With Moderna Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-11 11:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2023-01-10/us-inks-25-million-deal-to-fight-ebola-with-moderna-technology?srnd=technology-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138355693","content_text":"Texas scientists to study vaccines for several deadly virusesUS is seeking out greater protection from biological threatsUniversity of Texas researchers have clinched a US Department of Defense contract worth up to $25 million to develop vaccines using Moderna Inc.’s messenger RNA technology.Scientists at University of Texas Medical Branch at Galveston, in partnership with Moderna, were awarded $13.5 million over three years to design, manufacture and test mRNA vaccines for Ebola and other lethal pathogens. The project covers the shots’ development through Phase 1 clinical trials and UTMB could receive an additional $11.1 million to study alternative ways of administering the vaccines.The contract is part of a broader push by the US to protect military personnel using technology that enabled the quick development of Covid-19 vaccines early in the pandemic.“The high mortality rate and the potential use of these viruses as an agent of bioterrorism remains a risk that necessitates an urgent development of a vaccine,” the UTMB said in a statement Tuesday.Bloomberg first reported details of the US government contract in October.Funding for the UTMB-Moderna project will come from offices within the Department of Defense and Department of Health and Human Services, both of which have strategic investments in technology that could enhance US preparedness against biological threats. The work will be carried out at the UTMB’s Sealy Institute of Vaccine Sciences.The scientists will focus on a family of pathogens that includes Ebola, Sudan and Marburg, as well as Lassa viruses, all of which have long topped the list of vaccine priorities for the US government. The viruses cause sporadic outbreaks throughout the world — most recently in Uganda — and typically have a high death toll.There are currently no vaccines approved by the US Food and Drug Administration for Sudan virus, Marburg or Lassa fever. There is only one vaccine in the US that is licensed to protect against Ebola.Representatives from the Defense Department and Moderna didn’t immediately respond to request for comment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":52,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}